The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Corangin     [(1S,2R,5R,6S)-6-hydroxy- 4,8...

Synonyms: Etimonis, Isomonat, Isomonit, Monocord, Monolong, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Isomonat


Psychiatry related information on Isomonat


High impact information on Isomonat


Chemical compound and disease context of Isomonat


Biological context of Isomonat


Anatomical context of Isomonat


Associations of Isomonat with other chemical compounds


Gene context of Isomonat

  • In bFGF-mediated angiogenesis, L-NAME significantly, augmented angiogenesis, whereas ISMN significantly inhibited angiogenesis [27].
  • The pharmacokinetic parameters of two oral formulations of 20 mg tablets of isosorbide-5-mononitrate (CAS 16051-77-7, Dilavenil as test and another commercially available preparation as reference) were compared in an open-label, randomized, single oral dose, two-period cross-over design in 20 healthy volunteers under fasting conditions [28].

Analytical, diagnostic and therapeutic context of Isomonat

  • Both studies suggest that drug therapy can be improved by adding ISMN to b blockers in those patients with an insufficient decrease in HVPG [29].
  • METHODS: Repeated measurements of variceal radius, volume (by endosonography), and transmural pressure (using endoscopic gauge) were performed in 27 cirrhotic patients at baseline and 40 minutes after double-blind administration of placebo (n = 9), propranolol (n = 9), or ISMN (n = 9) [8].
  • Whether late reperfusion combined with prolonged unloading with isosorbide-5-mononitrate (ISMN) might produce greater functional recovery and less remodeling than late reperfusion alone is not known [5].
  • Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris. A randomized, double-blind, cross-over study. The Swedish Multicentre Group [30].
  • Thus, isosorbide-5-mononitrate administered by intravenous infusion under careful monitoring appears to have a beneficial role in the treatment of acute as well as chronic ischaemic heart failure [31].


  1. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. Villanueva, C., Balanzó, J., Novella, M.T., Soriano, G., Sáinz, S., Torras, X., Cussó, X., Guarner, C., Vilardell, F. N. Engl. J. Med. (1996) [Pubmed]
  2. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Angelico, M., Carli, L., Piat, C., Gentile, S., Capocaccia, L. Gastroenterology (1997) [Pubmed]
  3. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Angelico, M., Carli, L., Piat, C., Gentile, S., Rinaldi, V., Bologna, E., Capocaccia, L. Gastroenterology (1993) [Pubmed]
  4. Isosorbide-5-mononitrate in angina pectoris. Poss, M., Racicot, D., Kiser, W.R. Ann. Intern. Med. (1994) [Pubmed]
  5. Impact of left ventricular unloading after late reperfusion of canine anterior myocardial infarction on remodeling and function using isosorbide-5-mononitrate. Jugdutt, B.I., Khan, M.I., Jugdutt, S.J., Blinston, G.E. Circulation (1995) [Pubmed]
  6. Factorial design-based optimization of the formulation of isosorbide-5-mononitrate microcapsules. Farivar, M., Kaş, H.S., Oner, L., Hincal, A.A. Journal of microencapsulation. (1993) [Pubmed]
  7. Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Lui, H.F., Stanley, A.J., Forrest, E.H., Jalan, R., Hislop, W.S., Mills, P.R., Finlayson, N.D., Macgilchrist, A.J., Hayes, P.C. Gastroenterology (2002) [Pubmed]
  8. Endoscopic assessment of variceal volume and wall tension in cirrhotic patients: effects of pharmacological therapy. Escorsell, A., Bordas, J.M., Feu, F., García-Pagán, J.C., Ginès, A., Bosch, J., Rodés, J. Gastroenterology (1997) [Pubmed]
  9. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Navasa, M., Chesta, J., Bosch, J., Rodés, J. Gastroenterology (1989) [Pubmed]
  10. Effects of varying doses of spironolactone without and with nitrates on portal vein pressure and kidney function in partial portal vein ligated rats. Van de Casteele, M., Van Roey, G., Nevens, F., Fevery, J. Hepatology (1996) [Pubmed]
  11. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Salmerón, J.M., Ruiz del Arbol, L., Ginès, A., García-Pagán, J.C., Ginès, P., Feu, F., Claria, J., Rivera, F., Bosch, J., Arroyo, V. Hepatology (1993) [Pubmed]
  12. Lack of effects of isosorbide-5-mononitrate on hepatic hemodynamics in HBsAg-positive cirrhosis. Tsai, Y.T., Lee, F.Y., Lin, H.C., Chang, T.T., Lay, C.S., Wang, S.S., Kong, C.W., Lee, S.D., Lo, K.J. Hepatology (1989) [Pubmed]
  13. Massive ingestion of isosorbide-5-mononitrate and nitroglycerin: suicide attempt by an adolescent girl without previous heart disease. Sobrino, J.M., Fernández, N., Martinez, A., Pedrote, A. Eur. Heart J. (1992) [Pubmed]
  14. Isosorbide-5-mononitrate and nifedipine can reduce ischaemic ST-segment changes during Holter monitoring in patients with spontaneous angina pectoris. von Arnim, T., Erath, A., Reuschel-Janetschek, E. Eur. Heart J. (1988) [Pubmed]
  15. Acute effect of propranolol and isosorbide-5-mononitrate administration on renal blood flow in cirrhotic patients. Stanley, A.J., Bouchier, I.A., Hayes, P.C. Gut (1998) [Pubmed]
  16. Effect and mechanism of action of isosorbide-5-mononitrate. Hayes, P.C., Westaby, D., Williams, R. Gut (1988) [Pubmed]
  17. Mechanisms for the in vivo antiplatelet effects of isosorbide dinitrate. De Caterina, R., Giannessi, D., Mazzone, A., Bernini, W. Eur. Heart J. (1988) [Pubmed]
  18. Impaired vasodilator response to organic nitrates in isolated basilar arteries. Martens, D., Kojda, G. Br. J. Pharmacol. (2001) [Pubmed]
  19. Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. Kramer, W.G. Journal of clinical pharmacology. (1994) [Pubmed]
  20. Isosorbide-5-mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. Ribas, J., Angrill, J., Barberà, J.A., García-Pagán, J.C., Roca, J., Bosch, J., Rodriguez-Roisin, R. Eur. Respir. J. (1999) [Pubmed]
  21. Pharmacological evaluation of a novel oxime derived from isosorbide-5-mononitrate on isolated rat superior mesenteric artery. Petrović, R.M., Vujosević, Z.T., Milovanović, S., Ceković, Z., Bokonjić, D., Dobrić, S. Die Pharmazie. (2002) [Pubmed]
  22. The effect of isosorbide-mononitrate eye drops on the human intraocular pressure and aqueous humor dynamics. Diestelhorst, M., Hinzpeter, B., Krieglstein, G.K. International ophthalmology. (1991) [Pubmed]
  23. The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis. Grose, R.D., Plevris, J.N., Redhead, D.N., Bouchier, I.A., Hayes, P.C. J. Hepatol. (1994) [Pubmed]
  24. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Lin, H.C., Yang, Y.Y., Hou, M.C., Huang, Y.T., Lee, F.Y., Lee, S.D. Am. J. Gastroenterol. (2004) [Pubmed]
  25. Topical mononitrate treatment in patients with anal fissure. Tankova, L., Yoncheva, K., Muhtarov, M., Kadyan, H., Draganov, V. Aliment. Pharmacol. Ther. (2002) [Pubmed]
  26. Metabolism and disposition of 2',3'-di-O-nitro-adenosine-5'-(N-ethyl-carboxamide) in dogs. Wiener, H., Krivanek, P., Kolassa, N. Biochem. Pharmacol. (1983) [Pubmed]
  27. NO and de novo mammalian angiogenesis: further evidence that NO inhibits bFGF-induced angiogenesis while not influencing VEGF165-induced angiogenesis. Näslund, I., Norrby, K. APMIS (2000) [Pubmed]
  28. Evaluation of the bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers. Niopas, I., Daftsios, A.C., Nikolaidis, N. Arzneimittel-Forschung. (2002) [Pubmed]
  29. Prevention of variceal rebleeding. Bosch, J., García-Pagán, J.C. Lancet (2003) [Pubmed]
  30. Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris. A randomized, double-blind, cross-over study. The Swedish Multicentre Group. Nordlander, R., Walter, M. Eur. Heart J. (1994) [Pubmed]
  31. Haemodynamic effects of intravenous isosorbide-5-mononitrate in acute and chronic left heart failure of ischaemic aetiology. Rabinowitz, B., Katz, A., Shotan, A., Chouraqui, P., Neufeld, H.N. Eur. Heart J. (1988) [Pubmed]
WikiGenes - Universities